Search Results
Nov 12, 2025, 08:45 ET EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A
increasingly favorable, EirGenix is accelerating the development of four HER2-targeted antibody programs, expanding its in-house product pipeline as well as CDMO services for additional biosimilar projects. As global demand for biosimilar R&D and manufacturing continues to grow, EirGenix's technical expertise,
More news about: EirGenix, Inc.
Nov 12, 2025, 08:00 ET Genezen Announces Manufacturing Partnership with Humane Genomics to Advance Oncolytic Virus Therapy for Pediatric Liver Cancer
Nov. 12, 2025 /PRNewswire/ -- Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Humane Genomics, a biotechnology company developing oncolytic viral therapies, today announced a partnership for process transfer and cGMP manufacturing
More news about: Genezen
Nov 12, 2025, 07:47 ET EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A
increasingly favorable, EirGenix is accelerating the development of four HER2-targeted antibody programs, expanding its in-house product pipeline as well as CDMO services for additional biosimilar projects. As global demand for biosimilar R&D and manufacturing continues to grow, EirGenix's technical expertise,
More news about: EirGenix, Inc.
Nov 11, 2025, 23:45 ET Shilpa Pharma Lifesciences erhält die EcoVadis-Goldmedaille für herausragende Nachhaltigkeitspraktiken
„Nachhaltigkeit und Innovation sind wesentliche Bestandteile der Wachstumsstrategie von Shilpa als Auftragsentwicklungs- und Produktionsunternehmen (CDMO), um mit globalen innovativen Unternehmen bei deren Programmen für neue chemische Wirkstoffe zusammenzuarbeiten. Die EcoVadis-Goldmedaille ist ein Beweis
More news about: Shilpa Medicare Limited
Nov 11, 2025, 09:15 ET Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices
milestone, Mr. Keshav Bhutada, ED & CEO of Shilpa Pharma Lifesciences emphasized that "Sustainability and innovation are integral to Shilpa's CDMO growth strategy to work with global innovator companies for their New chemical Entity programs. The EcoVadis Gold Medal is a testimony to our relentless
More news about: Shilpa Medicare Limited
Nov 11, 2025, 04:15 ET Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices
milestone, Mr. Keshav Bhutada, ED & CEO of Shilpa Pharma Lifesciences emphasized that "Sustainability and innovation are integral to Shilpa's CDMO growth strategy to work with global innovator companies for their New chemical Entity programs. The EcoVadis Gold Medal is a testimony to our relentless
More news about: Shilpa Medicare Limited
Nov 10, 2025, 19:58 ET Avid Bioservices nombra a Dave Stewart como director de Tecnología y Transformación
de 2025 /PRNewswire/ -- Avid Bioservices, Inc., una organización líder en el desarrollo y fabricación por contrato de productos biológicos (CDMO), anunció hoy el nombramiento de Dave Stewart como director de Tecnología y Transformación, un puesto de nueva creación diseñado para impulsar la siguiente
More news about: Avid Bioservices
Nov 10, 2025, 19:55 ET Avid Bioservices ernennt Dave Stewart zum Chief Technology and Transformation Officer
11. November 2025 /PRNewswire/ -- Avid Bioservices, Inc., ein führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO) für Biologika, gab heute die Ernennung von Dave Stewart zum Chief Technology and Transformation Officer bekannt. Diese neu geschaffene Position soll
More news about: Avid Bioservices
Nov 10, 2025, 19:51 ET Avid Bioservices nomme Dave Stewart au poste de directeur de la technologie et de la transformation
Californie, 11 nov. 2025 /PRNewswire/ -- Avid Bioservices, Inc, une entreprise de sous-traitance pharmaceutique (CDMO) de premier plan, a annoncé aujourd'hui la nomination de Dave Stewart au poste de directeur de la technologie et de la transformation, un rôle nouvellement
More news about: Avid Bioservices
Nov 10, 2025, 12:00 ET Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
patients to be treated per vector batch, reducing cost of goods." "This advancement reinforces Ascend's position as a science-led CDMO committed to redefining what efficient, high-quality AAV manufacturing can look like," said Dr. Alessandra Rispoli, Chief Executive Officer at Ascend
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality
patients to be treated per vector batch, reducing cost of goods." "This advancement reinforces Ascend's position as a science-led CDMO committed to redefining what efficient, high-quality AAV manufacturing can look like," said Dr. Alessandra Rispoli, Chief Executive Officer at Ascend
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 12:00 ET Ascend stellt proprietäre Enhancer vor, die die AAV-Ausbeute deutlich verbessern, ohne die Qualität zu beeinträchtigen
Herstellungskosten senken würde." „Dieser Fortschritt stärkt die Position von Ascend als wissenschaftlich orientiertes CDMO-Unternehmen, das sich dafür einsetzt, die effiziente und qualitativ hochwertige Herstellung von AAV neu zu definieren", sagte Dr. Alessandra Rispoli, Chief
More news about: Ascend Advanced Therapies (Ascend)
Nov 10, 2025, 08:05 ET Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer
Nov. 10, 2025 /PRNewswire/ -- Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dave Stewart as Chief Technology and Transformation Officer, a newly created role designed to advance the company's
More news about: Avid Bioservices
Nov 10, 2025, 08:05 ET Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer
Nov. 10, 2025 /PRNewswire/ -- Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dave Stewart as Chief Technology and Transformation Officer, a newly created role designed to advance the company's
More news about: Avid Bioservices
Nov 10, 2025, 08:00 ET Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy
About Cellex Cell Professionals GmbH Cellex Cell Professionals is a leading, full service CDMO specializing in CGT. With its state-of-the-art facilities located in Cologne, Germany, and a proven track record of 10+ years in GMP-compliant autologous
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Das Cellex-Symposium 2025 führt internationale Experten zusammen, die über die Entwicklungen im Bereich der Zell- und Gentherapie diskutieren
Informationen zu Cellex Cell Professionals GmbH Cellex Cell Professionals ist eine führende, auf CGT spezialisierte CDMO mit umfassendem Service. Mit seinen hochmodernen Einrichtungen in Köln und einer nachgewiesenen Erfolgsbilanz von mehr als zehn Jahren in der GMP-konformen
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy
About Cellex Cell Professionals GmbH Cellex Cell Professionals is a leading, full service CDMO specializing in CGT. With its state-of-the-art facilities located in Cologne, Germany, and a proven track record of 10+ years in GMP-compliant autologous
More news about: Cellex Cell Professionals
Nov 10, 2025, 08:00 ET Cellex Symposium 2025: debate sobre el campo en evolución de la terapia celular y génica
Acerca de Cellex Cell Professionals GmbH Cellex Cell Professionals Cellex es una CDMO líder de servicio completo especializada en terapias celulares génicas (TCG). Con instalaciones de vanguardia en Colonia, Alemania, y una trayectoria
More news about: Cellex Cell Professionals
Nov 07, 2025, 06:09 ET Senores Pharma Reports Strong Q2 & H1 FY26 Performance, Sustains Growth Momentum Across Businesses
during the quarter, taking its portfolio to 32 own commercial products, 81 approved ANDAs, and 70 pipeline products, alongside 32 commercial CDMO/CMO products and 45 in the pipeline. Emerging Markets: The company's
More news about: Senores Pharmaceuticals Limited
Nov 06, 2025, 04:46 ET WuXi XDC Named the Winner of "Best CDMO" and "Best CRO" at 2025 World ADC Awards
Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that it has been named the winner of "Best CDMO" for the third consecutive year and the winner of "Best CRO" at 2025 World ADC Awards. In this year's World ADC Awards, WuXi XDC was the only service
More news about: WuXi XDC
Nov 06, 2025, 03:00 ET Abzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery through Development Solution
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, announced
More news about: Abzena
Nov 05, 2025, 12:57 ET Piramal Pharma Limited Announces Results for Q2 and H1 FY26
CDMO
More news about: Piramal Pharma Limited
Nov 05, 2025, 10:31 ET Hyaluronic Acid Products Market to Reach $20 billion, Globally, by 2034 at 7.7% CAGR: Allied Market Research
contract development and manufacturing organization ('CDMO'), announced that it has finalized a series of updated commercial arrangements with its long-term commercial Hyaluronic Acid and CDMO customer, Alcon to extend and expand the existing CDMO relationship. In addition, it also entered into a limited
More news about: Allied Market Research
Nov 05, 2025, 08:00 ET IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
capabilities covering vaccines, gene and immune therapeutics Strengthening global CDMO strategy through strategic synergy with SK bioscience Sustainable growth expected,
More news about: SK bioscience
Nov 05, 2025, 08:00 ET BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
Dr. Ziye Sui, Executive Director and CEO of Lepu BioPharma, commented: "We sincerely thank the BioDlink team for their outstanding CDMO services and strong collaboration. This approval also establishes a practical pathway for multi-party collaboration, offering new hope for R/M NPC patients
More news about: BioDlink Biopharm Co., Ltd.